Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Haloperidol for the treatment of delirium in critically ill patients: a systematic review with meta-analysis and Trial Sequential Analysis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Depth to the airway lumen at the level of the cricothyroid membrane measured by ultrasound

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-term patient-important outcomes after septic shock: a protocol for 1-year follow-up of the CLASSIC-trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The association between epidural analgesia and mortality in emergency abdominal surgery: A population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The association between epidural analgesia and mortality in emergency abdominal surgery: A population‐based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Trends and recommendations for critical care nursing research in the Nordic countries: Triangulation of review and survey data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dynamic LED-light versus static LED-light for depressed inpatients: study protocol for a randomised clinical study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sertraline in primary care: comments on the PANDA trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Haloperidol is the most frequently used drug to treat delirium in the critically ill patients. Yet, no systematic review has focussed on the effects of haloperidol in critically ill patients with delirium.

METHODS: We conducted a systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials (RCTs) assessing the effects of haloperidol versus any intervention on all-cause mortality, serious adverse reactions/events, days alive without delirium, health-related quality of life (HRQoL), cognitive function and delirium severity in critically ill patients with delirium. We also report on QTc prolongation, delirium resolution and extrapyramidal symptoms.

RESULTS: We included 8 RCTs with 11 comparisons (n=951). We adjudicated one trial as having overall low risk of bias. Three trials used rescue haloperidol; excluding these, we did not find an effect of haloperidol versus control on all-cause mortality (RR 1.01; 95% CI 0.33-3.06; I2 =0%; 112 participants; 3 trials; 4 comparisons; very low certainty) or delirium severity (SMD -0.15; 95% CI -0.61-0.30; I2 =27%; 134 participants; 3 trials; 4 comparisons; very low certainty). No trials reported adequately on serious adverse reactions/events. Only one trial reported on days alive without delirium, cognitive function and QTc prolongation, and no trials reported on HRQoL. Sensitivity analyses, including trials using rescue haloperidol, did not change the results.

CONCLUSIONS: The evidence for the use of haloperidol to treat critically ill patients with delirium is sparse, of low quality, and inconclusive. We therefore have no certainty regarding any beneficial, harmful or neutral effects of haloperidol in these patients.

OriginalsprogEngelsk
TidsskriftActa Anaesthesiologica Scandinavica
Vol/bind64
Udgave nummer2
Sider (fra-til)254-266
ISSN0001-5172
DOI
StatusUdgivet - 2020

Bibliografisk note

© 2019 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

ID: 58261819